Chronic Liver Disease and Hepatocellular Carcinoma
Although overall cancer incidence and mortality have steadily declined in the United States over the past 15 years, liver cancer incidence and mortality have been on the rise. Ethnic minority groups experience a disproportionate burden of chronic liver disease and liver cancer.
The May Laboratory focuses on developing clinical pathways to identify patients who are at risk for chronic liver disease and liver cancer. Radiographic and clinical lab information available in electronic medical records is used along with population risk data based on race, gender and age in an automated process to predict the likelihood of liver disease and liver disease progression.
Our liver disease research leverages population health, health disparities, clinical medicine, machine learning, and metabolomics to enhance risk prediction, provide insights regarding liver cancer oncogenesis and inform a precision-health approach to managing at-risk patients in the clinical setting.
- Yvonne Flores, PhD, Professor, Health Equity
- Roshan Bastani, PhD, Professor, Health Policy and Management
- Beth Glenn, PhD, Associate Professor, Health Policy and Management
- Arpan Patel, MD, Fellow in Transplant Hepatology, Mount Sinai Health System
- David Geffen School of Medicine Impact Grant; “Liver Cancer Prevention and Control - Understanding and Addressing Disparities” (Co-I)
- Bakr O, Gelberg L, Seragaki S, Youn S, Kawamoto J, Hoppe M, Altman L, Kopelson K, May FP, Cowan B, Bhattacharya D. Treating Hepatitis C in Homeless Veterans at the Greater Los Angeles Veterans' Affairs Medical Center. Hepatology. 2019 Apr 4;. doi: 10.1002/hep.30643. [Epub ahead of print] PubMed PMID: 30945758
- May FP, Rolston VS, Tapper EB, Lakshmanan A, Saab S, Sundaram V. The impact of race and ethnicity on mortality and healthcare utilization in alcoholic hepatitis: a cross-sectional study. BMC Gastroenterol. 2016 Oct 10;16(1):129. PMID:27724882
- Patel AA, Walling AM, May FP, Saab S, Wenger N. Palliative care and health care utilization for patients with end-stage liver disease at the end of life. Clin Gastroenterol Hepatol. 2017 Feb 4. [Epub ahead of print]. PMID: 28179192
- Sundaram V, May FP, Manne V, Saab S. Effects of clostridium difficile infection in patients with alcoholic hepatitis. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1745-52. PMID: 24681081
- Benhammou JN, Dong TS, May FP,Kawamoto J, Dixit R, Jackson S, Dixit V, Bhattacharya D, Han SB, Pisegna JR. Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. Pharmacol Res Perspect. 2018 Feb 22;6(2):e00379. doi: 10.1002/prp2.379. eCollection 2018 Apr. PMID: 29484189
- Dong TS, Aby ES, Benhammou JN, Kawamoto J, Han SH, May FP,Pisegna JR. Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c. World J Hepatol. 2018 Sept 27; 10(9):612-621. doi: 10.4254/wjh.v10.i9.612. PMID: 30310539